 OncLive | Everolimus Reduces Breast Cancer Effects in Bone The Oncology Report Adding everolimus to exemestane for the treatment of estrogen receptorāpositive advanced breast cancer that is refractory to nonsteroidal aromatase inhibitors has beneficial effects on bone turnover and breast cancer progression in bone, according to ... Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast Cancer Afinitor's new UK indication launched Novartis launches breast cancer drug Afinitor in UK |
